Exhibit 10.1

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE (1) SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, OR (2) DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS AS [***].

Proposal: HEBA_7869_v3.D.24072026

24th July 2026

Revision history

Table of contents

Scheme 1. Synthesis of PolyI

Scheme 2. Synthesis of Poly C12U

1. Company Summary

Sterling Pharma Solutions has over 50 years’ experience of supporting our customers globally with projects from pre-clinical to commercial manufacture. Each year we develop, scale up and manufacture to cGMP over 150 stages of chemistry. In the last four years we have supported our customers through clinical supply and launch with 16 new chemical entities.

Differentiated by the three core characteristics of service, passion, and science, we are more than a traditional CDMO. We are a PDMO®, or partnership development and manufacturing organization. That means we are uniquely responsive to your needs, committed to your product, and capable of adding a deep level of scientific value.

Whilst science can be complex, we believe partnerships should be simple.

To watch a short animation about Sterling please click here.

2. Executive summary

AIM Immunotech Inc (“AIM Immunotech”) has requested that Sterling Pharma Solutions (“Sterling”) provide a proposal for the manufacture of further batches of the polynucleotide drug substances PolyI and Poly C12U. The syntheses of PolyI and Poly C12U are depicted in Schemes 1 and 2.

This proposal is based on manufacture of the polymers in aqueous frozen solution at the Dudley site.

Remainder of page intentionally left blank.

3 Research and Development Plan

3.1 Polyl and Poly C12U process development

Efforts will initially focus on the following development and optimization activities. The investigation work will commence following evaluation and confirmation of suitability of the analytical methods to support this work. Sterling would be pleased to discuss and further refine or adjust the activities captured in this section:

Polyl

Poly C12U

Assumptions:

Deliverables:

Remainder of page intentionally left blank.

3.2 Polyl and Poly C12U non-GMP demonstration batches

Sterling will manufacture a non-GMP demonstration batch of each process in laboratory glassware of 20 liters, to verify the performance of each process and control strategy, as well as to verify the validity of the assumptions made below.

Assumptions:

Deliverables:

Remainder of page intentionally left blank.

3.3 Polyl Stage 1 and Poly C12U Analytical Method Implementation and Validation.

Sterling will implement AIM Immunotech provided phase appropriate analytical methods for the PolyI and Poly C12U products. and will utilize AIM Immunotech provided fit for purpose analytical reference standards. The development and validation of several methods has also been identified as a project requirement (Table 1).

Assumptions:

Table 1. Analytical validation requirements

Assumptions:

Deliverables:

4. Manufacturing plan

Sterling strives for right-first-time execution with a focus on safety and quality. The technical transfer from development to manufacture is performed through a series of governance processes and continued technical, EHS and quality management before, during and after manufacturing. The estimated production and material resources are based upon the learnings from laboratory familiarization work, including the activities listed below.

The following manufacturing support activities are included:

Remainder of page intentionally left blank.

4.1 cGMP Manufacture of Polymer Solutions

Manufacture of the polymer solutions will be carried out in Sterling’s GMP Pilot Plant facility, located at the Dudley, UK site. A reactor stream featuring [***] liter vessels will be assigned, with the additional equipment required for the processes. In each case the target batch size will be preparation of [***] liters of solution containing [***] of polymer. All steps will be carried out under cGMP conditions. Completed batches of polymer solution will be held in suitable containers and frozen for storage and onward transportation for lyophilization.

Prior to manufacture Sterling will prepare the following documentation, which will be sent to AIM Immunotech for review and approval:

The asset and batch plan are detailed in the table below and estimated plant occupancy is reflected in the pricing and invoicing section.

Table 2. Asset strategy for the GMP manufacturing campaign

1Estimated cycle times include commissioning and cleaning time.

Assumptions:

Deliverables:

Table 3. Investment requirements for the GMP manufacturing campaign

Storage and shipment agreement:

Storage is free for up to two months from the date of manufacture. Storage beyond two months will be billed at the end of each month at a rate listed in the below table.

Table 4. Product storage

Storage of materials in advance of three months from the date of manufacture will incur an additional Value Added Tax (VAT) charge, which is required by UK Government, of 20% of the goods’ sales value. This will be passed through at cost. Recovery of any VAT charged to the Client is the responsibility of the Client.

Preparation of a single bulk shipment of each lot of material manufactured under this Proposal is included in the total price. Bulk shipments of material will be dispatched under Incoterms FCA 2020 (Sterling Dudley), or will be charged back at [***].

Preparation of bulk material for shipment will be billed per request at a rate of $[***] each. This rate includes the time required to weigh, sample and label the material in a GMP compliant environment. Multiple preparations from the same bulk, if requested and sampled simultaneously, will incur a single $[***] preparation charge. Each shipment will also be back charged at [***].

Preparation of laboratory samples for shipment will be billed at a rate of $[***] per sample, per shipment, plus freight costs and a [***].

Pricing and invoicing

Sterling has made various estimates and assumptions in preparing this Proposal, including the value and volume of materials to be used and the amount of time above activities will utilise its facilities and personnel. Based on such estimates and assumptions, the Pricing Summary below provides the indicative price to provide the development, testing, and manufacturing activities by Sterling with supporting materials, supplies, and waste included unless explicitly listed otherwise. Sterling will endeavor to ensure the price quoted below is the maximum price and will regularly review and monitor any potential for increased costs, however, some variables are not within Sterling’s control and therefore if the estimates and assumptions can be demonstrated to be inaccurate, Sterling reserves the right to update the Pricing Summary, discuss with AIM Immunotech and invoice AIM Immunotech accordingly. Further if additional or out of scope activities and/or materials are required due to unforeseen outcomes or at the request of AIM Immunotech, Sterling will discuss with AIM Immunotech and provide a change order to support that work or activity.

Any third-party services and shipping handled by Sterling not explicitly listed below will be passed through at cost plus a handling fee.

Table 5. Pricing summary

1The total value (manufacturing and materials) represented in these lines shall be considered the value used in the calculation of the “Cancellation Fee” as captured in the Terms and Conditions (attached hereto) 2This pricing is based upon a GBP (£) to USD ($) conversion rate of x1.33; a mutually agreed currency adjustment will be applied for any fluctuations above agreed limits (e.g. supplementary invoices/credit notes, alternatively pricing will be based on the exchange rate on the date invoices are raised).

Table 6. Price component summary

Remainder of page intentionally left blank.

Table 7. Invoice schedule for scope of work

Scope changes:

All changes from this scope of work will be documented by Sterling and approved by AIM Immunotech prior to commencement of any such additional work.

Remainder of page intentionally left blank.

6 Project Management

Sterling will appoint a dedicated project manager to manage the project through all project stages. Standardized tools, techniques, detailed processes and procedures will be used to track, monitor, and communicate project progress throughout the lifecycle of the contract.

6.1 Communication management plan

Upon initiation, a detailed communication management plan will be created to support the project. This is expected to include, but is not limited to the following:

These processes will support, but not replace, formal communication outlined in the quality agreement.

This communications management plan sets the communications framework for this project. It will serve as a guide for communications throughout the life of the project and will be updated as communication requirements change. This plan identifies and defines the roles of the project team members as they pertain to communications. It also includes a communications matrix which maps the communication requirements of this project, and communication conduct for meetings and other forms of communication.

The assigned project manager will take the lead role in ensuring effective communications on this project. The communications matrix will be used as the guide for what information to communicate, who is to do the communicating, when to communicate it, and to whom to communicate.

6.2 Schedule

Based on the information provided by Client, assumptions made by Sterling, and the consultation of subject matter experts, a tentative schedule has been prepared to highlight significant milestones surrounding the proposal. Post-acceptance of this proposal, the assumptions will be reviewed and the schedule will be updated to reflect current timing and milestones accordingly. Any delay to the items indicated in the table below will have a direct impact to the overall timeline and delivery of the bulk API.

6.3 High level initial assumptions/tentative schedule:

The Gantt chart provided in this proposal is based off of assumptions (development time, cycle time, yields, etc.) derived from the information provided by the client and assumes approval by Client within 30 days. Should capacity or availability of resources change due to signature of other projects prior to execution of this proposal Sterling will notify Client and discuss any potential impacts.

[*** the blacked out portions of the image below have been redacted]

7 Signature page

This proposal shall become binding on the parties if signed by an authorized representative of AIM Immunotech and returned to Sterling within 30 days of the date hereof.

Acceptance:

If acceptable, please indicate by signing below and issuing a purchase order or payment method referencing this proposal number.

An authorized representative of Sterling will sign upon proposal receipt from AIM Immunotech to formally accept the proposal.

By signing this proposal, the parties acknowledge the services provided hereunder shall be subject to the Terms and Conditions in Appendix A.

Further information

About Sterling

Our facilities

Partnership development and manufacturing organisation (PDMO) Our heritage

Executive team

Small Molecule Services

API Development

API Manufacturing

CMC

Solid state chemistry

Milling and micronisation

ADCs

ADC Development

ADC Analytical Services

Technologies

Hazardous chemistry

Diazomethane

Hazard evaluation

Chiral chemistry

Controlled substances

Continuous processing/flow

Biocatalysis

Highly Potent API (HPAPI)

Fluorination

Knowledge Hub

All resources

Quality and regulatory

HSE

Latest news

Appendix A: Terms and Conditions

https://www.sterlingpharmasolutions.com/core/wp-content/uploads/2026/03/Sterling-Proposal-TCs-Dudley-Cramlington-Jan-2026.pdf

Remainder of page intentionally left blank.